Valore202020212022202320242025TTMSpese di vendita, generali e amministrative743.57 M860.09 M863.75 M929.87 M995.27 M720.17 M720.17 MRicerca e sviluppo119.75 M130.84 M153.82 M154.35 M161.67 M144.78 M144.78 MReddito operativo423.07 M628.1 M499.73 M506.31 M151.01 M118.37 M-114.14 MProventi non operativi, Totale20.34 M20.62 M21.79 M-13.65 M-107.31 M28.62 M28.62 MOneri finanziari, al netto degli interessi capitalizzati66.49 M56.97 M54.26 M85.08 M83.54 M100.22 M100.22 MProventi non operativi, esclusi gli oneri finanziari-46.16 M-36.34 M-32.47 M-98.73 M-190.86 M-71.6 M-71.6 MEntrate/uscite straordinarie———————Utile al lordo delle imposte357.73 M559.47 M445.92 M434.01 M75.48 M24.55 M24.55 MQuota di utile———————Imposte21.93 M74.35 M83 M76.44 M5.32 M-33.98 M-33.98 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate335.8 M485.12 M362.92 M357.57 M70.16 M58.53 M-194.74 MAttività cessate-477 K255 K223 K-1.24 M-487 K-964.17 M-710.9 MUtile netto335.32 M485.37 M363.14 M356.33 M69.67 M-905.64 M-905.64 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari335.32 M485.37 M363.14 M356.33 M69.67 M-905.64 M-905.64 MUtile base per azione (EPS base)7.2110.387.747.581.49-20.3-20.54Utile diluito per azione (EPS diluito)7.0910.237.687.531.48-20.25-20.55Numero medio di azioni ordinarie in circolazione46.49 M46.77 M46.9 M46.98 M46.84 M44.62 M178.91 MAzioni diluite in circolazione47.29 M47.43 M47.31 M47.3 M47.09 M44.72 M179.22 MEBITDA427.5 M632.59 M503.78 M525.32 M394.43 M127.87 M1.39 BEBIT195.82 M390.73 M269.13 M279.8 M116.41 M-54.54 M912.02 MCosto del fatturato1.21 B1.26 B1.26 B1.33 B1.34 B871.96 M871.96 MAltri costi del venduto———————Ammortamento e svalutazione (liquidità)231.68 M241.85 M234.64 M245.52 M278.02 M182.41 M478.02 M
Teleflex Incorporated
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer is Liam J. Kelly; Kelly is also the company's president and former chief operating officer.